Updates in Myelodysplastic Syndromes: Improving Patient Outcomes

This activity, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease. Start the activity now.

STATEMENT OF NEED

Myelodysplastic syndromes (MDS) comprise a heterogeneous group ofmyeloid malignanciesthat derive from abnormal multipotent progenitor cells and are characterized by bone marrow failure and peripheral blood cytopenias (NCCN, 2021; Garcia-Manero et al, 2021). Survival in MDS ranges from a median of 8.8 years in the lowest-risk patients to as little as 0.8 years in the highest-risk patients (ACS, 2018). Data has shown that clinicians may benefit from education that helps them determine the clinical relevance of the latest advances in MDS treatment (i3 Health, 2021). In this activity, MikkaelSekeres, MD, MS, will help learners to enhance patients’ outcomes by exploring predictive and prognostic markers that can individualize MDS treatment, analyzing the latest safety and efficacy data for emerging MDS therapies, and developing strategies to optimize safety and tolerability for novel MDS treatments.

TARGET AUDIENCE

Hematologist/oncologists, hematology/oncology fellows, nurse practitioners, physician assistants, pharmacists, oncology nurses, and other health care professionals involved in the treatment of patients with hematologic malignancies.

LEARNING OBJECTIVES

Upon completion of this activity, participants should be able to
Discuss predictive and prognostic markers that can individualize treatment selection for patients with MDS
Assess emerging efficacy and safety data on novel therapeutic strategies for MDS
Evaluate strategies to optimize the safety and tolerability of novel therapies for MDS